早期结直肠癌预后预测中临床病理、基因组、转录组亚型与微环境的相对贡献
该回顾性生物标志物分析纳入 adjuvant 化疗未治疗(N=1656)和治疗(N=980)的 II 期(N=1799)和 III 期(N=837)结直肠癌,评估 CMS 评分、CD8+ 细胞毒性淋巴细胞和癌症相关成纤维细胞浸润评分对无病生存的预测价值。多变量模型显示仅临床病理和微环境细胞为显著预后因素,MSI 和 CMS 组的预后价值很大程度上可由 CytoLym 和 CAF 浸润模式解释。
要点
- 仅临床病理和微环境细胞(CytoLym+CAF)是多变量模型中的显著预后因素。
- MSI 和 CMS 组的预后价值很大程度上由 CytoLym 和 CAF 浸润模式解释。
核心结论
- 肿瘤微环境浸润模式是早期结直肠癌远处播散风险的强决定因素。
- MSI 和 CMS 组的预后价值很大程度上可由 CytoLym 和 CAF 浸润模式解释。
研究设计与样本
- 回顾性生物标志物分析,纳入 adjuvant 化疗未治疗(N=1656)和治疗(N=980)的 II 期(N=1799)和 III 期(N=837)结直肠癌。
- 从 bulk 肿瘤组织转录组定义 CMS 评分并估计 CD8+ 细胞毒性淋巴细胞和癌症相关成纤维细胞浸润评分。
- 构建分层多变量 Cox 模型分析无病生存,并计算各标志物解释变异比例。
主要发现
- 多变量模型中仅临床病理和微环境细胞(CytoLym+CAF)为显著预后因素。
- II 期 DFS 模型解释变异:临床病理 77%、微环境细胞 14%、基因组标志物 5.3%、CMS4 评分 3.7%。
- III 期 DFS 模型解释变异:临床病理 55.9%、微环境细胞 35.1%、基因组标志物 4.1%、CMS4 评分 0.9%。
- 微卫星稳定肿瘤中 CytoLym 高评分与预后改善信号最强(交互 P=0.04),高 CAF 评分的不良预后仅限于 III 期(交互 P=0.04)。
临床怎么用
- 在早期结直肠癌预后评估中可考虑整合肿瘤微环境浸润模式(CytoLym 和 CAF)以补充 TNM 分期。
- MSI 和 CMS 分型的预后信息可能部分通过微环境浸润模式体现,解读时需综合考虑。
局限性
- 回顾性研究设计。
- 微环境评分基于 bulk 肿瘤组织转录组估计,非直接病理评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains unknown to what extent consensus molecular subtype (CMS) groups and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor-node-metastasis (TNM) staging and microsatellite instability (MSI) status in early-stage colorectal cancer (CRC). PATIENTS AND METHODS: We carried out a comprehensive retrospective biomarker analysis of prognostic markers in adjuvant chemotherapy-untreated (N = 1656) and treated (N = 980), stage II (N = 1799) and III (N = 837) CRCs. We defined CMS scores and estimated CD8+ cytotoxic lymphocytes (CytoLym) and cancer-associated fibroblasts (CAF) infiltration scores from bulk tumor tissue transcriptomes (CMSclassifier and MCPcounter R packages); constructed a stratified multivariable Cox model for disease-free survival (DFS); and calculated the relative proportion of explained variation by each marker (clinicopathological [ClinPath], genomics [Gen: MSI, BRAF and KRAS mutations], CMS scores [CMS] and microenvironment cells [MicroCells: CytoLym+CAF]). RESULTS: In multivariable models, only ClinPath and MicroCells remained significant prognostic factors, with both CytoLym and CAF infiltration scores improving survival prediction beyond other markers. The explained variation for DFS models of ClinPath, MicroCells, Gen markers and CMS4 scores was 77%, 14%, 5.3% and 3.7%, respectively, in stage II; and 55.9%, 35.1%, 4.1% and 0.9%, respectively, in stage III. Patients whose tumors were CytoLym high/CAF low had better DFS than other strata [HR=0.71 (0.6-0.9); P = 0.004]. Microsatellite stable tumors had the strongest signal for improved outcomes with CytoLym high scores (interaction P = 0.04) and the poor prognosis linked to high CAF scores was limited to stage III disease (interaction P = 0.04). CONCLUSIONS: Our results confirm that tumor microenvironment infiltration patterns represent potent determinants of the risk for distant dissemination in early-stage CRC. Multivariable models suggest that the prognostic value of MSI and CMS groups is largely explained by CytoLym and CAF infiltration patterns.
引用
- Dienstmann R, Villacampa G, Sveen A, et al. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann Oncol. 2019. PMID: 31504112. doi:10.1093/annonc/mdz287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。